We are advising InSilico Medicine in connection with its $60 million Series D financing

Davis Polk is advising InSilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, in connection with its $60 million Series D financing from a syndicate of global investors with expertise in investing in the biopharmaceutical and life sciences sectors. New investors, including a large, diversified asset management firm on the U.S. West Coast and BHR Partners joined the round, along with current investors, including lead investor of Series C financing round Warburg Pincus, B Capital Group, Qiming Venture Partners, BOLD Capital Partners and Pavilion Capital. Insilico's founder and CEO, Alex Zhavoronkov, Ph.D., also invested in the Series D round.

Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases and aging-related diseases.

The Davis Polk corporate team includes partners James C. Lin, Miranda So and Howard Zhang and registered foreign lawyers Michael Zhuoran Xu, Yi-Ping Chang and Yin Wu. Counsel Alon Gurfinkel and associates Omer Harel and Kelli A. Rivers are providing tax advice. Members of the Davis Polk team are based in the Hong Kong, Beijing and London offices.